Another exciting and highly selective CDK9 inhibitor is SLS009, which has a Phase 2 trial in combination with VenAza for R/R AML, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and lymphoma in pediatric and adult populations, including three patients with TP53 mutations (NCT04588922) [190]. The gene discussed is CDK9; the disease is B-cell chronic lymphocytic leukemia.